Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3156 participants.

Also called NCT07252544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07252544
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07252544. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-01 (anticipated); primary completion 2027-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
Condition
Stroke, Lacunar
Condition
Stroke, Acute Ischemic
Condition
Cerebral Small Vessel Diseases
Intervention (Drug)
Isosorbide Mononitrate
Intervention (Drug)
Butylphthalide
Intervention (Drug)
Isosorbide Mononitrate Placebo
Intervention (Drug)
Butylphthalide Placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Shenzhen Second People's Hospital (class: other)

Record details

Record id
cardio:ct-nct07252544
Content hash
95d06380a885826c526f8ea2c155c16bfb35345ab81397822df8cb6bedba9ff8